女性用避妊薬の世界市場予測(~2027年)

• 英文タイトル:Female Contraceptive Market Research Report by Contraceptive Drug, Contraceptive Devices, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Female Contraceptive Market Research Report by Contraceptive Drug, Contraceptive Devices, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「女性用避妊薬の世界市場予測(~2027年)」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301B110
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、230ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iリサーチ社の本調査資料では、2021年に8,266.40百万ドルであった女性用避妊薬の世界市場規模が、2022年に8,773.28百万ドルになり、2027年には11,932.56百万ドルまで、年平均6.30%で拡大すると予測しています。本資料では、世界の女性用避妊薬市場について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、避妊薬別(避妊注射、経口避妊薬、殺精子剤、局所避妊薬)分析、避妊具別(避妊パッチ、避妊スポンジ、ダイヤフラム&キャップ、女性用コンドーム、その他)分析、流通チャネル別(診療所、病院薬局、独立薬局、オンラインプラットフォーム)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況などを掲載しています。また、本書の企業情報には、Allergan plc、Bayer AG、Cipla Limited、HLL Lifecare Limited、Johnson & Johnson、Mankind Pharma、Merck Sharp & Dohme Corp、Mithra Pharmaceuticals S.A.、Pfizer Inc.、Reckitt Benckiser Group plcなどがあります。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の女性用避妊薬市場規模:避妊薬別
- 避妊注射の市場規模
- 経口避妊薬の市場規模
- 殺精子剤の市場規模
- 局所避妊薬の市場規模
・世界の女性用避妊薬市場規模:避妊具別
- 避妊パッチの市場規模
- 避妊スポンジの市場規模
- ダイヤフラム&キャップの市場規模
- 女性用コンドームの市場規模
- その他避妊具の市場規模
・世界の女性用避妊薬市場規模:流通チャネル別
- 診療所チャネルの市場規模
- 病院薬局チャネルの市場規模
- 独立薬局チャネルの市場規模
- オンラインプラットフォームチャネルの市場規模
・世界の女性用避妊薬市場規模:地域別
- 南北アメリカの女性用避妊薬市場規模
アメリカの女性用避妊薬市場規模
カナダの女性用避妊薬市場規模
ブラジルの女性用避妊薬市場規模
...
- アジア太平洋の女性用避妊薬市場規模
日本の女性用避妊薬市場規模
中国の女性用避妊薬市場規模
インドの女性用避妊薬市場規模
韓国の女性用避妊薬市場規模
台湾の女性用避妊薬市場規模
...
- ヨーロッパ/中東/アフリカの女性用避妊薬市場規模
イギリスの女性用避妊薬市場規模
ドイツの女性用避妊薬市場規模
インドの女性用避妊薬市場規模
フランスの女性用避妊薬市場規模
ロシアの女性用避妊薬市場規模
...
- その他地域の女性用避妊薬市場規模

・競争状況
・企業情報

The Global Female Contraceptive Market size was estimated at USD 8,266.40 million in 2021 and expected to reach USD 8,773.28 million in 2022, and is projected to grow at a CAGR 6.30% to reach USD 11,932.56 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Female Contraceptive to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Contraceptive Drug, the market was studied across Contraceptive Injections, Contraceptive Pills, Spermicides, and Topical Contraceptives. The Contraceptive Pills is further studied across Hormonal Pills and Non-hormonal Pills.

Based on Contraceptive Devices, the market was studied across Contraceptive Patches, Contraceptive Sponges, Diaphragms and Caps, Female Condoms, Intra Uterine Contraceptive Devices (IUCDs), Sub-dermal Contraceptive Implants, and Vaginal Rings.

Based on Distribution Channel, the market was studied across Clinic, Hospital Pharmacy, Independent Pharmacy, and Online Platform.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Female Contraceptive market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Female Contraceptive Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Female Contraceptive Market, including Allergan plc, Bayer AG, Cipla Limited, HLL Lifecare Limited, Johnson & Johnson, Mankind Pharma, Merck Sharp & Dohme Corp, Mithra Pharmaceuticals S.A., Pfizer Inc., and Reckitt Benckiser Group plc.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Female Contraceptive Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Female Contraceptive Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Female Contraceptive Market?
4. What is the competitive strategic window for opportunities in the Global Female Contraceptive Market?
5. What are the technology trends and regulatory frameworks in the Global Female Contraceptive Market?
6. What is the market share of the leading vendors in the Global Female Contraceptive Market?
7. What modes and strategic moves are considered suitable for entering the Global Female Contraceptive Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of unwanted pregnancies and sexually transmitted diseases
5.1.1.2. Rising government initiatives to promote awareness regarding unintended pregnancies and increasing population
5.1.1.3. Multiple types and ease of availability of contraceptives
5.1.2. Restraints
5.1.2.1. Side effects of contraceptive drugs
5.1.3. Opportunities
5.1.3.1. Availability of contraceptives method such as Sino-Implants and novel contraceptive
5.1.3.2. Government and non-government organizations supporting programs to encourage contraception in emerging economies
5.1.4. Challenges
5.1.4.1. Social stigma and misconceptions about different contraceptives
5.2. Cumulative Impact of COVID-19

6. Female Contraceptive Market, by Contraceptive Drug
6.1. Introduction
6.2. Contraceptive Injections
6.3. Contraceptive Pills
6.4.1. Hormonal Pills
6.4.2. Non-hormonal Pills
6.4. Spermicides
6.5. Topical Contraceptives

7. Female Contraceptive Market, by Contraceptive Devices
7.1. Introduction
7.2. Contraceptive Patches
7.3. Contraceptive Sponges
7.4. Diaphragms and Caps
7.5. Female Condoms
7.6. Intra Uterine Contraceptive Devices (IUCDs)
7.7. Sub-dermal Contraceptive Implants
7.8. Vaginal Rings

8. Female Contraceptive Market, by Distribution Channel
8.1. Introduction
8.2. Clinic
8.3. Hospital Pharmacy
8.4. Independent Pharmacy
8.5. Online Platform

9. Americas Female Contraceptive Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Female Contraceptive Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Female Contraceptive Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Allergan plc
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Bayer AG
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Cipla Limited
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. HLL Lifecare Limited
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Johnson & Johnson
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Mankind Pharma
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Merck Sharp & Dohme Corp
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Mithra Pharmaceuticals S.A.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Pfizer Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Reckitt Benckiser Group plc
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing




• 英文レポート名:Female Contraceptive Market Research Report by Contraceptive Drug, Contraceptive Devices, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
• 日本語訳:女性用避妊薬の世界市場予測(~2027年)
• レポートコード:MRC2301B110お問い合わせ(見積依頼・ご注文・質問)